Active Immunization in Pregnancy

  • Michael W. Varner
Part of the Clinical Perspectives in Obstetrics and Gynecology book series (CPOG)


More human lives have been saved or prolonged as a result of advances in infectious disease control or prevention than in any other area of medicine. Two major advances responsible for this claim are the development of effective antimicrobials and the development of effective immunization against infectious diseases with previously high morbidity and mortality rates. This chapter will review immunization with particular emphasis on pregnancy, beginning with a review of molecular mechanisms of immunization, and the use of specific vaccines during pregnancy.


Pregnant Woman Yellow Fever Rubella Virus Rubella Vaccine Smallpox Vaccination 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Gall SA. Maternal adjustments in the immune system in normal pregnancy. Clin Obstet Gynecol. 1983; 26: 521–536.PubMedCrossRefGoogle Scholar
  2. 2.
    Amstey MS. Vaccination in pregnancy. Clin Obstet Gynaecol. 1983; 10: 13–22.PubMedGoogle Scholar
  3. 3.
    Faber JJ, Thornburg KL. Transplacental transmission of protein. In: Faber JJ, Thornburg KL. Placental physiology. New York: Raven Press, 1983: 97–114.Google Scholar
  4. 4.
    Mickelson KNP, Moriarty KM. Immunoglobulin level in human colostrum and milk. J Pediatr Gastroenterol Nutr. 1982; 1: 381–384.CrossRefGoogle Scholar
  5. 5.
    Alford CA, Griffiths PD. Rubella. In: Remington JS, Klein JO. Infectious diseases of the fetus and newborn infant. Philadelphia: Saunders, 1983: 69–103.Google Scholar
  6. 6.
    Rubella vaccination during pregnancy—United States, 1971-1983. MMWR. 1984; 33: 365–373.Google Scholar
  7. 7.
    Rubella prevention. MMWR. 1984; 33: 301–318.Google Scholar
  8. 8.
    Buimovic-Klein E, Hite RL, Byrne T, et al. Isolation of rubella virus in milk after postpartum immunization. J Pediatr. 1977; 91: 939–941.CrossRefGoogle Scholar
  9. 9.
    Naderi S. Smallpox vaccination during pregnancy. Obstet Gynecol. 1975; 46: 223–226.PubMedGoogle Scholar
  10. 10.
    Goldstein JA, Neff JM, Lane JM, et al. Smallpox vaccination reactions, prophylaxis, and therapy of complications. Pediatrics. 1975; 55: 342.PubMedGoogle Scholar
  11. 11.
    Levine MM, Edsall G, Bruce-Chwatt LJ. Live- virus vaccines in pregnancy: risks and recommendations. Lancet. 1974, 2: 34.PubMedCrossRefGoogle Scholar
  12. 12.
    Mumps vaccine. MMWR. 1982; 31: 617–625.Google Scholar
  13. 13.
    Yellow fever vaccine. MMWR. 1984; 32: 679–688.Google Scholar
  14. 14.
    Scolnick EM, McLean MM, West DJ, et al. Clinical evaluation in healthy adults of a hepatitis B vaccine made by recombinant DNA. JAMA 1984; 251: 2812–2815.PubMedCrossRefGoogle Scholar
  15. 15.
    Beasley RP, Hwang L-Y, Lin C-C, et al. Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22,707 men in Taiwan. Lancet. 1981; 2: 1129.PubMedCrossRefGoogle Scholar
  16. 16.
    Postexposure prophylaxis of hapatitis B. MMWR. 1984; 33: 285–290.Google Scholar
  17. 17.
    Harris JW. Influenza occurring in pregnant women. A statistical study of 1350 cases. JAMA 1919; 72: 978–980.Google Scholar
  18. 18.
    Freeman DW, Barno A. Deaths from Asian influenza associated with pregnancy. Am J Obstet Gynecol. 1959; 78: 1172–1175.PubMedGoogle Scholar
  19. 19.
    Prevention and control of influenza. Ann Intern Med. 1984; 101: 218–22.Google Scholar
  20. 20.
    Varner MW, McGuinness GA, Galask RP. Rabies vaccination in pregnancy. Am J Obstet Gynecol. 1982; 143: 717–718.PubMedGoogle Scholar
  21. 21.
    Gupte SC, Bahtia HM. Increased incidence of hemolytic disease of the newborn caused by ABO incompatibility when tetanus toxoid is given during pregnancy. Vox Sang. 1980; 38: 22.PubMedCrossRefGoogle Scholar
  22. 22.
    Baker CJ, Kasper DL. Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N Engl J Med. 1976; 294: 753–756.PubMedCrossRefGoogle Scholar
  23. 23.
    Baker CJ, Edwards MS, Kasper DL. Role of antibody to native type III polysaccharide of group B streptococcus in infant infection. Pediatrics. 1981; 68: 544 - 549.PubMedGoogle Scholar
  24. 24.
    Santos JI, Shigeoka AO, Rote NS, et al. Protective efficacy of a modified immune serum globulin in experimental group B streptococcal infection. J Pediatr. 1981; 99: 873–879.PubMedCrossRefGoogle Scholar
  25. 25.
    Baker CJ, Edwards MS, Kasper DL. Immuno- genocity of polysaccharide from type III group B Streptococcus. J Clin Invest. 1978; 61: 1107–1110.PubMedCrossRefGoogle Scholar
  26. 26.
    Plotkin SA, Farquhar J, Hornberger E. Clinical trials with the Towne 125 stain of human cytomegalovirus. J Infect Dis. 1976; 134: 470–475.PubMedCrossRefGoogle Scholar
  27. 27.
    Lang DJ. Cytomegalovirus immunization: status, prospects and problems. Rev Infect Dis. 1980; 2: 449–458.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag New York, Inc. 1986

Authors and Affiliations

  • Michael W. Varner

There are no affiliations available

Personalised recommendations